1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Analysis of the Global Oncology Drug Delivery Market : Future Impact of Emerging Technologies

Methodology

Analysis contained in this research service is based on the following:
• Information collected through discussions with market participants and from secondary sources, including pharmaceutical companies and medical devices companies involved in drug delivery systems as well as other Websites and credible sources.
• Public announcements and plans by key market leaders, suppliers, new entrants, and others.
• Frost & Sullivan’s published research and market and technology expertise.
All market figures and shares listed in the research are Frost & Sullivan's assessment based on its research.
For Market Engineering research, Frost & Sullivan utilises tried and tested marketing techniques to provide structure to the research and an easy format to compare results across different countries and markets. This project was carried out using primary (telephone) and secondary (published and online material) research as the principle methods of data gathering. The focus of the interviews for this project was primarily the respondent types outlined below.
• Industry participants
• End-users
• Key regulatory bodies
• Frost & Sullivan published research services
• Decision support databases
• Country industry forecasts
• Annual reports published by companies

Key Findings

•The total global oncology drug delivery market (or oncolytics market) was worth $ x billion in 2013 and has been growing at an annual rate of x %. The market was estimated at $ x billion in 2014 (including drug delivery systems for cancer therapy and cancer pain).
•The oral oncology drug delivery segment accounted for x % of the total market and is expected to continue its strong growth in 2015.
•The United States accounted for the largest revenue share in the total market with $ x billion in 2013.
•An estimated x drugs for treating or preventing cancer are in the pipeline globally. Of these, about x % have the potential to be first-in-class treatments if they successfully reach Phase 3 trials. Currently, US biopharmaceutical companies have an estimated x drugs and vaccines for treating or preventing cancer in clinical trials or awaiting Food and Drug Administration (FDA) review.
•Traditionally, intravenous (IV) and injected treatments were considered the primary methods of chemotherapy delivery; these methods are covered under a health plan’s medical benefit, where the patient is only required to co-pay. In addition, the prescribers considered that the efficacy (bio-availability) of drugs is better with injectables.
•As patient-administered (self-injectable and oral drug delivery systems) anti-cancer medications are often covered under a health plan’s prescription benefit, many patients end up paying out-of-pocket for the high and unmanageable co-pays; in some cases, this results in spends upwards of hundreds or thousands of dollars per month. As a result, it has been estimated that more than x % of the patients in the United States choose not to fill their initial prescriptions for oral anti-cancer medications due to the high rates of cost-sharing and opt for injectables instead.
•Currently, the injectable segment leads the oncology drug delivery market; however, nano-particles (micro-needles, patches, and orals) is expected to lead the market in the future.
•F. Hoffmann-La Roche AG, Novartis AG, and Celgene Corporation are the top three participants, collectively accounting for more than x % of the total market, followed by Johnson & Johnson, AstraZeneca Plc, Bristol-Myers Squibb, and Pfizer, Inc.
•The Essemblix Drug Development Platform, nanodaises, nano-cocoons, and micro bubble liposome particle delivery are some of the potential technologies that can prove to be game changers in the future.

Key Questions This Study Will Answer

Is the market growing? How long will it continue to grow, and at what rate?
Who are the key competitors in this market?
What are the major drivers and restraints in this market?
Which is the most attractive segment in the total oncology drug delivery market?
What are the upcoming technologies in the oncology drug delivery market?

Table Of Contents

Analysis of the Global Oncology Drug Delivery Market : Future Impact of Emerging Technologies
Methodology 7
Executive Summary 8
• Key Findings 9
• Key Findings—Options in Oncology Drug Delivery Market 11
• Scope and Segmentation 12
• Key Questions This Study Will Answer 13
• Market Engineering Measurements 14
• CEO's Perspective 15
• Key Technologies To Watch 16
• 3 Key Predictions 17
Market Overview 18
• Market Background 19
• Market Segmentation 20
• Oncology Drug Delivery Market—Segmentation by Type of Delivery 21
• Oncology Drug Delivery Market—Segmentation by Region 23
• Oncology Drug Delivery Market—Segmentation by Top 5 Competitors 24
• Cancer Pain Management Market 25
Competitive Playbook 26
• New Market Opportunities 27
• Pipeline of Products in Oncology Drug Delivery Market 28
• Attractiveness in Oncology Drug Delivery Market 29
Drivers and Restraints 30
• Market Drivers 31
• Drivers Explained 32
• Market Restraints 34
• Restraints Explained 35
Forecast and Trends—Total Cancer Drug Delivery Market 36
• Market Engineering Measurement 37
• Forecast Assumptions 38
• Revenue Forecast 39
• Revenue Forecast By Key Segment 40
• Revenue Forecast Discussion 41
• Oral or Injectable Drug Delivery System: New Options for Payors 42
• Porter's 5 Force Analysis 46
Injectable Drug Delivery System Segment Analysis 47
• Market Engineering Measurements 48
• Injectable Drug Delivery Forecast 49
• Revenue Forecast Discussion 50
• Injectable Drug Delivery System—Competitive Assessment 51
Oral Drug Delivery Systems Segment Analysis 52
• Market Engineering Measurements 53
• Oral Drug Delivery Forecast 54
• Revenue Forecast Discussion 55
• Oral Oncolytic—Past, Present, and Future Options 56
• Oral Drug Delivery System Segment—Competitive Assessment 57
Opportunities By Regions 58
• US Market 59
• Europe Market 61
• Rest-of-World (RoW) Market 63
Opportunity By Technology 65
• Nano Drug Delivery: Future Of Cancer Drug Delivery Systems 66
• Currently Marketed Nano Drug Delivery Systems 67
• Nano Drug Delivery System—by Segmentation 68
• Attractive Nano Drug Delivery Systems 69
• Key Nano Drug Delivery Systems 70
• Intra Nasal Drug Delivery: Next Option In Cancer Pain 71
Key Companies to Watch 72
• Becton, Dickinson and Company 73
• Evotech A G 74
• Juno Therapeutics 75
• West Pharmaceuticals 76
• NEONC Technologies Inc. 77
Conclusion 78
• Future of Cancer Drugs 79
• Conclusion 80
• Frost and Sullivan Awards 81
• Legal Disclaimer 82
Appendix 83

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.